Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution

Many drugs have been marketed for treating coronavirus disease 2019 (COVID-19) infection, the disease that has caused a worldwide pandemic. However, in reported clinical trials, almost 30% of patients with COVID-19 did not show any health improvement. The 28-day survival rate was 69.5% when patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichiyama, Takashi, Komatsu, Masamichi, Wada, Yosuke, Hanaoka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Respiratory Society. Published by Elsevier B.V. 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035365/
https://www.ncbi.nlm.nih.gov/pubmed/35501265
http://dx.doi.org/10.1016/j.resinv.2022.04.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035365/
https://www.ncbi.nlm.nih.gov/pubmed/35501265
http://dx.doi.org/10.1016/j.resinv.2022.04.001

Ejemplares similares